Loading organizations...
§ Venture Capital · Washington, DC, USA
Venture capital firm investing in biotech, medtech, and healthtech companies to advance human medicine.
Hatteras Venture Partners is a venture capital firm based in Durham, North Carolina, that invests in biotech, medtech, and healthtech companies to advance human medicine. The firm partners with visionary founders, providing capital and hands-on support for team recruitment, business development, regulatory planning, and portfolio strategy. To date, Hatteras has strategically invested in 61 companies across its 9 closed funds, including the recent Hatteras Opportunity Fund I which closed in March 2024. Their portfolio features successful ventures such as G1 Therapeutics and PhaseBio Pharmaceuticals, underscoring their focus on impactful medical advancements. General Partners Clay Thorp, Christy Shaffer, and Alston Gardner are among the key individuals guiding the firm's investment strategy. Hatteras Venture Partners was founded in 2000 by Clay Thorp and John Crumpler.
Key people at Hatteras Venture Partners.
Hatteras Venture Partners is a venture capital firm specializing in seed and early-stage investments primarily in the life sciences and healthcare sectors, including biotechnology, medical devices, and health technology. Their mission is to build transformational human medicine companies that benefit patients and healthcare professionals. With over $900 million under management across seven funds, Hatteras supports innovative startups by providing strategic guidance and capital to help navigate the complexities of healthcare markets. The firm has a strong track record, having invested in over 100 companies, including notable successes like HistoSonics, Kymera Therapeutics, and G1 Therapeutics, which have achieved significant milestones such as IPOs and acquisitions[1][2][3].
Founded in 2000 and based in Durham, North Carolina, Hatteras Venture Partners began as a seed-stage venture fund with less than $3 million in capital. Over 25 years, it has evolved into a leading healthcare-focused VC firm managing nearly a billion dollars. The firm was established by a team of experienced entrepreneurs and operators with deep expertise in seed and early-stage investing and company formation. Its focus has consistently been on fostering innovation in human medicine, expanding from a regional presence in the Southeast to nationwide investments in cutting-edge healthcare startups[1][2][3].
Hatteras Venture Partners rides the ongoing trend of innovation in healthcare and life sciences, a sector driven by advances in biotechnology, medical devices, and health IT. The timing is critical as the healthcare industry faces increasing demand for novel therapies and technologies to address complex diseases and improve patient outcomes. Market forces such as aging populations, rising healthcare costs, and technological breakthroughs create fertile ground for early-stage investments. Hatteras influences the ecosystem by enabling startups to translate breakthrough science into viable medical products, thereby accelerating the pace of innovation in human medicine[1][2][3].
Looking ahead, Hatteras is well-positioned to continue capitalizing on emerging trends in biotechnology and health technology, including precision medicine, immunotherapies, and digital health solutions. Their recent capital raise of over $200 million underscores confidence from limited partners despite a challenging fundraising environment. As healthcare innovation accelerates, Hatteras’s role as an early-stage investor and strategic partner will likely grow, helping to shape the future of medical treatments and technologies. Their influence will deepen as they back startups progressing toward clinical milestones and commercial success, reinforcing their mission to transform human medicine[1][4].
Key people at Hatteras Venture Partners.
Hatteras Venture Partners has more than 26 tracked investments across 22 companies. The latest tracked deal is $20.0M Series A in Pharaoh Neuro in February 2026.